Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027297 | 0.88 | RXFP1 (0.40) | RXFP1ALDH1A1HPGDTP53PTK2 | |
| SCHEMBL12478676 | 0.83 | HPGD (0.36) | ALDH1A1HPGDTDP1MAPTLMNA | |
| SCHEMBL27949157 | 0.82 | ALDH1A1 (0.35) | ALDH1A1HPGDTDP1MAPTABL1 | |
| SCHEMBL15524202 | 0.77 | ACACB (0.45) | RXFP1ALDH1A1HPGDMAPTPOLB | |
| SCHEMBL12478002 | 0.74 | PTK2 (0.54) | PTK2FLT4 | |
| SCHEMBL15524335 | 0.74 | BTK (0.42) | NTRK1PTK2FLT4 | |
| SCHEMBL14576448 | 0.73 | PTK2 (0.52) | PTK2 | |
| SCHEMBL15524760 | 0.73 | PTK2 (0.47) | PTK2FLT4 | |
| SCHEMBL15524527 | 0.73 | PTK2 (0.44) | PTK2 | |
| SCHEMBL14617541 | 0.73 | RXFP1 (0.41) | RXFP1ALDH1A1HPGDTDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| EP-2675794-A1 | SELECTIVE FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| WO-2012110774-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | RXFP1 1530/4885ALDH1A1 2548/4885HPGD 3212/4885 |
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | RXFP1 934/4885ALDH1A1 3192/4885HPGD 3082/4885 |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | RXFP1 1208/4885ALDH1A1 3249/4885HPGD 3306/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | RXFP1 934/4885ALDH1A1 3192/4885HPGD 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.